Health Dictionary Find a Doctor

Multiple sclerosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Future or Investigational Therapies

Therapies under investigation:

References

  1. United Kingdom early Mitoxantrone Copaxone trial. Onyx Healthcare (2006-01-01). Retrieved on 2007-09-02.
  2. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN. Genzyme (2007-02-01). Retrieved on 2007-09-02.
  3. Daclizumab. PDL Biopharma (2006-01-01). Retrieved on 2007-09-02.
  4. Treatment of Multiple Sclerosis Using Over the Counter Inosine. ClinicalTrials.gov (2006-03-16). Retrieved on 2007-09-02.
  5. Efficacy and Safety of BG00012 in Relapsing-Remitting Multiple Sclerosis. ClinicalTrials.gov (2007-09-01). Retrieved on 2007-11-12.
  6. Efficacy and Safety of Fingolimod in Patients With Relapsing-Remitting Multiple Sclerosis. ClinicalTrials.gov (2006-02-09). Retrieved on 2007-09-02.
  7. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T (2005). “Treatment with laquinimod reduces development of active MRI lesions in relapsing MS”. Neurology. 64 (6): 987–91. doi:10.1212/01.WNL.0000154520.48391.69. PMID 15781813.
  8. Darlington CL (2005). “Technology evaluation: NeuroVax, Immune Response Corp”. Curr. Opin. Mol. Ther. 7 (6): 598–603. PMID 16370383.
  9. Agrawal YP (2005). “Low dose naltrexone therapy in multiple sclerosis”. Med. Hypotheses. 64 (4): 721–4. doi:10.1016/j.mehy.2004.09.024. PMID 15694688.
  10. search of clinicaltrials.gov data-base for Low dose naltrexone Multiple Sclerosis

Template:WH Template:WS

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH